Overview

• the formulation co-delivers STING and TLR4 agonists to trigger multi-pathway immune activation and robust tumor-specific T‑cell priming.
• In prophylactic melanoma tests using defined peptides, 80% of vaccinated mice stayed tumor-free for the full 250-day study.
• With tumor-lysate vaccines, rejection rates reached 88% in pancreatic, 75% in triple-negative breast, and 69% in melanoma models.
• Vaccinated mice showed complete protection against metastatic lung tumors after systemic melanoma exposure, unlike controls.
• The UMass Amherst team reported the findings on October 9 and formed NanoVax Therapeutics to advance therapeutic and translational work.